As of April 30, 2021, the registrant had 92,817,493 shares of common stock outstanding. None of these distributors is an end user of our products. There are generally three major negotiating entities in the US market. Red Oak Sourcing consists of CVS and Cardinal's source programs. Finally, ClarusOne consists of Walmart, RiteAid and McKesson's OneStop program. A loss of any of these major entities could result in a significant reduction in revenue. We are also exploring the options to monetize certain of our non-core assets. The sterile production area is designed around isolator-based technology. We have also implemented a more frequent sanitization process of the facility. Our goal is to become a leader in the generic pharmaceutical market. Generic pharmaceutical products are bioequivalent to their brand name counterparts. Our suppliers are subject to similar regulations and periodic inspections. Formulary listings are also used by private payors to reimburse generic products. We now own a total of 11.44 acres at our Buena facility. We rely on a limited number of customers for a large portion of our revenues. The pharmaceutical industry in which we operate is intensely competitive. We could experience business interruptions at our manufacturing facility. Such disruptions and breaches of security could adversely affect our business. A motion to dismiss the Humana Inc. and The Kroger Co., et al. The third claim has proceeded to a damages phase, which is ongoing. The plaintiff seeks to recover compensable damages. As to the negligence claim, New Mexico seeks unspecified monetary damages. MINE SAFETY DISCLOSURES Not applicable. The repurchase of the 2019 Notes was considered a debt extinguishment under ASC 470-50. The Term Loans are governed by the Second Lien Credit Agreement. On April 6, 2020, the Company entered (i) Amendment No. 2 of the Revolver and Amendment No. 5 to Second Lien Credit Agreement (the "Second Lien Amendment"). The Company was in compliance with its financial covenants as of December 31, 2020. The Company does not require collateral from its customers. The Company analyzes the adequacy of its accruals for returns and allowances quarterly. Accruals are also adjusted to reflect actual results. Rebates are used for various discounts and rebates provided to customers. As a result, we have no market risk related to the Series A Notes. The Revolver was fully drawn in 2019. He leads the Legal, Human Resources, IT and Investor Relations teams. Mr. Celentano currently works as an advisor to the pharmaceutical industry. Nominating and Corporate Governance Committee. Mr. Yachmetz also agrees to assign certain intellectual property to the Company. 3) Includes information with respect to the 2016 Equity Incentive Plan. incorporated by reference to Exhibit 10.32 to the Company 10-K, filed March 12, 2017). ( 8226; We tested payments processed throughout the year. The Company operates its business under one segment. The Company has also implemented a routine sanitization process of the facility. These products include both injectable and topical prescription medicines. Inc., Teligent Luxembourg S.à.r.l., The carrying value of goodwill at December 31, 2020 was $0.5 million. Transaction costs are expensed as incurred. These large wholesalers represent the majority of the Company's chargeback payments. There were no RSUs outstanding at December 31, 2020. It has additional offices located in Iselin, New Jersey and Mississauga, Canad
